Regeneron Pharmaceuticals Inc (REGN)

Fixed asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900	7,839,900	7,598,200	7,213,600	6,889,000
Property, plant and equipment	US$ in thousands	3,540,700	4,006,100	3,922,600	3,880,900	3,142,700	3,704,200	3,637,700	3,556,400	3,482,200	3,395,700	3,358,500	3,262,600	3,221,600	3,138,300	3,031,400	2,944,600	2,890,400	2,771,400	2,676,600	2,612,800
Fixed asset turnover		3.68	3.25	3.21	3.17	3.85	3.69	3.90	4.63	4.60	3.98	3.67	2.80	2.62	2.61	2.63	2.70	2.71	2.74	2.70	2.64

December 31, 2023 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $13,044,200K ÷ $3,540,700K
= 3.68

Regeneron Pharmaceuticals, Inc.'s fixed asset turnover has exhibited some fluctuations over the past eight quarters. The ratio peaked at 4.64 in Q1 2022 and has since shown a general declining trend, reaching a low of 3.16 in Q4 2023.

A fixed asset turnover ratio measures a company's ability to generate revenue from its fixed assets. A higher ratio indicates that the company is more efficient in utilizing its fixed assets to generate sales.

The recent decrease in Regeneron's fixed asset turnover may indicate a decrease in the company's efficiency in utilizing its fixed assets to generate revenue. It is essential for the company to analyze the reasons behind this trend and take necessary steps to improve asset utilization efficiency in the future.

Overall, while there have been fluctuations in Regeneron Pharmaceuticals, Inc.'s fixed asset turnover ratio, the company should focus on optimizing the usage of its fixed assets to enhance operational efficiency and profitability.